What is PT-141 and how is it different from erectile dysfunction drugs?

PT-141 (Bremelanotide) is a melanocortin receptor agonist peptide that works through the central nervous system to increase sexual arousal and desire. Unlike PDE5 inhibitors (Viagra, Cialis) that work by increasing blood flow to genital tissues, PT-141 acts on melanocortin receptors in the brain to enhance libido in both men and women. It was FDA-approved in 2019 as Vyleesi for premenopausal women with hypoactive sexual desire disorder (HSDD). For men, it's used off-label for erectile dysfunction and libido enhancement. Administration is via subcutaneous injection about 45 minutes before anticipated sexual activity. Effects typically last 2-4 hours. Side effects include nausea (common), flushing, and increased blood pressure. PT-141 is unique among sexual health treatments because it targets desire rather than just physical function. It doesn't cause the blood pressure drops or vision changes associated with PDE5 inhibitors. However, the injection route and nausea limit its widespread adoption compared to oral ED medications.